MSD

Showing 15 posts of 243 posts found.

merckentranceweb

MSD to bring over 400 new jobs to North Carolina with two site expansions

July 31, 2019
Manufacturing and Production, Research and Development MSD, US, pharma

MSD has announced a $650 million expansion of its existing facilities in North Carolina – a move which is bring …

merck-keytruda

MSD’s Keytruda combo hits primary endpoint at Phase 3 in triple-negative breast cancer

July 30, 2019
Manufacturing and Production, Research and Development Cancer, MSD, breast cancer, keytruda, pharma

MSD’s blockbuster anti-PD-L1 immunotherapy Keytruda (pembrolizumab) has impressed in newly released Phase 3 data; the company announced that, when combined …

humira_abbott__4

Humira biosimilar from Samsung Bioepis and MSD wins marketing authorisation in the US

July 24, 2019
Research and Development, Sales and Marketing AbbVie, Humira, MSD, Samsung Bioepis, biosimilars, pharma

It’s another victory for MSD as the US drugmaker announced that its biosimilar version of AbbVie’s Humira – the world’s …

1920px-hiv-budding-color

MSD trials long lasting PrEP implant for preventing HIV

July 23, 2019
Research and Development AIDS, HIV, MSD, PrEP, pharma

MSD is trialling an implant that prevents patients from contracting HIV, The Guardian has said. The US firm has tested …

merckentranceweb

FDA approves MSD’s combo therapy Recarbrio for urinary tract and intra-abdominal infections

July 18, 2019
Sales and Marketing FDA, MSD, Recarbrio, US, pharma, urinary tract

MSD has announced the approval from the FDA of its combination therapy Recarbrio (imipenem, cilastatin and relebactam) in the treatment …

US Judge blocks Trump administration law requiring pharma to include prices in TV ads

July 9, 2019
Manufacturing and Production Amgen, Eli Lilly, MSD, TV ads, Trump, USA, court, pharma

A judge has blocked the Trump administration from enacting a law that would require pharmaceutical companies to include the prices …

merck-keytruda

MSD’s Keytruda snatches up first approval in small cell lung cancer

June 19, 2019
Research and Development, Sales and Marketing Cancer, FDA, MSD, US, keytruda, lung cancer, pharma

MSD has revealed that its anti-PD-1 immunotherapy Keytruda (pembrolizumab) has been awarded marketing authorisation from the FDA as a monotherapy …

lynparza

EU approval for MSD and AZ’s Lynparza in first-line BRCA-mutated advanced ovarian cancer

June 18, 2019
Manufacturing and Production, Sales and Marketing AstraZeneca, Cancer, MSD, lynparza, ovarian cancer, pharma

AstraZeneca and MSD’s jointly-developed therapy Lynparza (olaparib) has scored its third EU approval, the pair announced, with authorisation for the …

29496564944_a9faceb1c2_z

Drugmakers sue Trump over prices in TV ads

June 17, 2019
Sales and Marketing Amgen, Eli Lilly, HHS, MSD, Merck, Trump, pharma

Amgen, Eli Lilly and MSD have sued the Trump administration to try and block measures to force pharma companies to …

merckincweb2

FDA ask MSD to join blockchain supply chain network

June 14, 2019
Medical Communications FDA, MSD, Merck, blockchain, supply chain

The FDA has asked MSD to join a shared permission blockchain network to help track and trace prescription medicines and …

shutterstock_273326141

MSD scoops up biopharma firm Tilos for $773 million

June 10, 2019
Sales and Marketing MSD, Tilos Therapeutics, acquisition, pharma

US-based firm MSD has announced it intends to acquire biopharma firm Tilos Therapeutics, and has signed a deal with the …

merckentranceweb

Longest follow up trial of Merck’s Keytruda sets new standard for five year survival in lung cancer

June 3, 2019
Sales and Marketing KEYNOTE, MSD, Merck, keytruda, lung cancer

Nearly a quarter of previously untreated lung cancer patients who took Keytruda (Pembrolizumab) were alive after five years, according to …

merckwindow_web

NICE recommends MSD’s Prevymis for CMV prevention following allogeneic haematopoietic stem cell transplant

May 31, 2019
Medical Communications, Sales and Marketing MSD, NICE, Prevymis, UK, cmv, cytomegalovirus, pharma

MSD has revealed that its non-nucleoside CMV inhibitor Prevymis (letermovir) has secured recommendation from NICE, meaning it will now be …

4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

May 24, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Gilead, J&J, JJ, MSD, Sandoz, pharma, top ten

On the day that UK Prime Minister Theresa May announces her resignation, we look back on the week’s biggest stories …

Latest content